Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report
Open Access
- 24 February 2015
- journal article
- case report
- Published by Springer Nature in International Journal of Bipolar Disorders
- Vol. 3 (1) , 4
- https://doi.org/10.1186/s40345-014-0020-y
Abstract
There is an increasing use of ayahuasca for recreational purposes. Furthermore, there is a growing evidence for the antidepressant properties of its components. However, there are no reports on the effects of this substance in the psychiatric setting. Harmaline, one of the main components of ayahuasca, is a selective and reversible MAO-A inhibitor and a serotonin reuptake inhibitor. We present the case of a man with bipolar disorder who had a manic episode after an ayahuasca consumption ritual. This patient had had at least one hypomanic episode in the past and is currently depressed. We discuss the diagnostic repercussion of this manic episode. There is lack of specificity in the diagnosis of substance-induced mental disorder. The knowledge of the pharmacodynamic properties of ayahuasca consumption allows a more physiopathological approach to the diagnosis of the patient.Keywords
This publication has 12 references indexed in Scilit:
- Diagnostic and Statistical Manual of Mental DisordersPublished by American Psychiatric Association Publishing ,2013
- β-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)Food and Chemical Toxicology, 2010
- A case of β-carboline alkaloid intoxication following ingestion of Peganum harmala seed extractForensic Science International, 2008
- Oxidative stress in psychiatric disorders: evidence base and therapeutic implicationsInternational Journal of Neuropsychopharmacology, 2008
- Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloidsAddiction, 2006
- Phytochemical Analyses ofBanisteriopsis CaapiandPsychotria ViridisJournal of Psychoactive Drugs, 2005
- Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challengesPharmacology & Therapeutics, 2004
- Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and PharmacokineticsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptorsDrug and Alcohol Dependence, 2000
- Selective and Nonselective Monoamine Oxidase InhibitorsArchives of General Psychiatry, 1982